| Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer H Kodaz, O Kostek, MB Hacioglu, B Erdogan, CE Kodaz, I Hacibekiroglu, ... Breast cancer 7 (12), 1-7, 2017 | 68 | 2017 |
| Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib A Gökyer, A Küçükarda, O Köstek, MB Hacıoğlu, BS Sunal, NC Demircan, ... Clinical and Translational Oncology 21, 1518-1523, 2019 | 23 | 2019 |
| K-RAS and N-RAS mutations in testicular germ cell tumors BM Hacioglu, H Kodaz, B Erdogan, A Cinkaya, E Tastekin, I Hacibekiroglu, ... Bosnian journal of basic medical sciences 17 (2), 159, 2017 | 21 | 2017 |
| Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? O Köstek, MB Hacıoğlu, A Sakin, T Demir, M Sarı, O Ozkul, M Araz, ... Cancer chemotherapy and pharmacology 83, 115-122, 2019 | 20 | 2019 |
| Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma A Küçükarda, B Erdoğan, A Gökyer, S Sayın, İ Gökmen, E Özcan, ... Supportive Care in Cancer, 1-9, 2022 | 19 | 2022 |
| Clinical features of the patient with multiple primary tumors: Single center experience A Gokyer, O Kostek, MB Hacioglu, B Erdogan, H Kodaz, E Turkmen, ... Northern clinics of Istanbul 4 (1), 43, 2017 | 16 | 2017 |
| Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey MB Hacıoğlu, O Köstek, S Karabulut, D Taştekin, S Sezgin Göksu, ... Journal of BU ON., 2020 | 11 | 2020 |
| Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study K Sinan, B Mehmet, Ö Melike, K Mustafa, B Mehmet, H Bekir, D Gamze, G, ... Journal of Oncology Pharmacy Practice, 2020 | 10* | 2020 |
| Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102 EB Hacioglu MB, Kostek O, Kurt N, Kucukarda A, Gokyer A, Ustabasioglu FE ... JBUON 24 (5), 2198-2204, 2019 | 10* | 2019 |
| Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer O Köstek, E Yılmaz, MB Hacıoğlu, NC Demircan, A Gökyer, S Uzunoğlu, ... Cancer chemotherapy and pharmacology 83, 735-742, 2019 | 10 | 2019 |
| Invasive pleomorphic lobular histology is an adverse prognostic factor on survival in patients with breast cancer S Sahin, F Karatas, GU Erdem, B Hacioglu, K Altundag The American Surgeon 83 (4), 359-364, 2017 | 9 | 2017 |
| Enzalutamide in prostate cancer, a review on enzalutamide and cancer B Erdogan, O Kostek, M Bekirhacioglu Eurasian j med oncol 2 (3), 121-9, 2018 | 8 | 2018 |
| Predictive and prognostic factors in ovarian and uterine carcinosarcomas İ Cicin, T Özatli, E Türkmen, T Özturk, M Özçelik, D Çabuk, ... Balkan Medical Journal 33 (5), 517-524, 2016 | 8 | 2016 |
| Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less E Özaslan, H Karaca, S Koca, A Sevinç, B Hacioglu, M Özkan, M Özçelik, ... Anti-Cancer Drugs 28 (2), 222-229, 2017 | 7 | 2017 |
| Krukenberg tumor presenting with amenorrhea as the sole initial symptom: Case report and review of the literature S Sahin, F Karatas, B Hacioglu, A Aytekin, I Imamoglu, N Koseoglu, E Sari, ... Journal of cancer research and therapeutics 11 (4), 1024, 2015 | 7 | 2015 |
| Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated … A Küçükarda, A Gökyer, I Gökmen, E Özcan, MB Hacıoğlu, B Erdoğan, ... Actas Urológicas Españolas (English Edition) 46 (5), 301-309, 2022 | 6 | 2022 |
| Is the charlson comorbidity index a prognostic indicator for toxicity and mortality in elderly patients with locally advanced rectal cancer? O Köstek, Y Bozkaya, MB Hacıoğlu, NY Özdemir, E Yılmaz, NC Demircan, ... Archives of Iranian Medicine 22 (5), 236-241, 2019 | 6 | 2019 |
| Durable complete response with a short course of streptozotocin plus doxorubicin combination in malignant metastatic insulinoma F Karatas, S Sahin, A Aytekin, MB Hacioglu, GI Imamoglu, M Altinbas Journal of Cancer Research and Therapeutics 14 (5), 1149-1151, 2018 | 6 | 2018 |
| Assessment of prognostic factors in epithelial ovarian cancer Y Onal, O Kostek, MB Hacioglu, B Erdogan, H Kodaz, ET Bekmez, ... Eurasian J Med Oncol 1 (2), 61-8, 2017 | 6 | 2017 |
| A rare coexistence-Chronic lymphocytic leukemia and Kaposi sarcoma: Case report and review of the literature MB Hacioglu, S Sahin, F Karatas, A Aytekin Journal of cancer research and therapeutics 11 (4), 954-956, 2015 | 6 | 2015 |
